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Background: Heparin is widely used for the prophylaxis of venous thrombo-embolism 
and pulmonary embolism. Thrombocytopaenia and the sequale of thrombosis are 
uncommon adverse effects of therapy which are associated with high morbidity and 
mortality. 
Objective: To review the clinical-pathologic features of heparin induced 
thrombocytopaenia/thrombosis. 
Data sources: Reputable haematology journals and the internet in English. Searches 
included thrombosis, heparin, and heparin induced thrombocytopaenia. 
Data selection: Only relevant journals and internet sources were selected for this 
review. In particular leading journals in thrombosis and anticoagulants. 
Data extraction: High quality abstracts, papers and internet articles were the main 
source of information. 
Data synthesis: Information from the selected abstracts and papers was used for the 
paper. 
Conclusion: The clinical effects of heparin induced thrombocytopaenia/thrombosis 
(HIT/T) include venous and arterial events the latter of which include limb ischaemia, 
myocardial infarction and stroke. The pathogenesis of this complication is related 
the formation of heparin-platelet factor 4 antibodies which can be demonstrated in 
the laboratory by functional and immunoassays. Management requires alternative 
anticoagulation with agents that have no cross reactivity with heparin platelet factor 4 
antibodies. These agents include danapranoid, direct thrombin inhibitors and newer 
agents like fondaparinux and rivaroxaban with anti Xa activity. 
INTRODUCTION
Heparin, is a naturally occurring protein with a 
molecular weight of 6-30 kda. It is a highly sulfated 
glycosaminoglycan composed of alternating uronic 
acid and glucosamine residues. Heparin was 
introduced into clinical practice in the 1960’s and 
is now firmly established in the the management of 
venous thromboembolism (1).
 Unfractionated heparin, (UFH) is effective in 
the prevention and treatment of venous thrombo 
embolism (VTE). UFH has also been in use for the 
early treatment of patients with unstable angina and 
acute myocardial infarction, for patients who have 
cardiac surgery under cardiac bypass, in patients 
who have vascular surgery, during and after coronary 
angioplasty, in patients with coronary stents and for 
flushing of intravenous catheters in intensive care 
unit and renal settings.
 Low molecular weight heparin, (LMWH) is 
presently produced by chemical or enzymatic digestion 
of UFH and have molecular weights of less than 8.0 kda. 
In 1986, nandroparin was approved as the first LMWH 
for peri and post operative VTE prophylaxis. Since 
then LMWH have been widely used as anticoagulants 
for venous VTE, pulmonary embolism and for 
haemodialysis/haemofilteration (2).
 Despite the therapeutic benefits as an 
anticoagulant, there are a number of side effects 
associated with the use of heparin. These include 
bleeding, allergic reactions, skin necrosis, osteoporosis 
and thrombocytopaenia.
 Thrombocytopaenia is a well recognised and 
serious complication of heparin therapy and occurs 
regardless of the dose, age, gender or route of 
administration. This phenomenon associated with 
heparin therapy is known as the syndrome of heparin 
induced thrombocytopaenia (HIT).
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 Paradoxically some of the patients with heparin 
induced thrombocytopaenia develop arterial or 
venous thrombosis. Failure of early recognition of this 
complication results in variable but relevant rates of 
morbidity and mortality.
 Heparin induced thrombocytopaenia with 
thrombosis, (HIT/T) was described in 1958 by 
Weismann and Tobin in 10 patients who developed 
emboli while on treatment with heparin. This 
complication was described as the white clot 
syndrome due to the appearance of white platelet 
thrombi occluding the lumen of blood vessels. Six 
of the patients died as a result of recurrent multiple 
arterial emboli (3). In 1964 Roberts et al (4) described 
an additional 11 patients who manifested arterial 
thrombo emboli following heparin therapy.  Rhodes 
et al (5) observed the relationship between the 
development of thrombocytopaenia and thrombosis 
in the early 1970s.
 The last 40 years has witnessed a considerable 
interest and awareness of HIT with over 1000 
publications on the topic, since the first case 
described by Weismann and Tobin (3). Today there 
is better understanding of its clinical presentation, 
pathophysiology and management options.
CLINICAL FEATURES OF HIT
Incidence of heparin induced antibody formation, 
thrombocytopaenia and thrombosis: The overall 
frequency of HIT is difficult to precisely define because 
the risk is associated with the type of heparin, the 
dose of heparin, study design and most importantly 
the clinical situation (6).
 The first prospective study investigating the 
incidence of thrombocytopaenia during heparin 
therapy was reported by Bell et al in 1976. The 
incidence of thrombocytopaenia (platelet count of 
< 100 x 109/l) was found to be 30.7%. Subsequent 
studies found that the incidence of heparin induced 
thrombocytopaenia was lower than this initial report 
particularly with the recognition of the immune 
mechanisms of thrombocytopaenia.
 In a review of 14 prospective clinical studies 
reported between 1980 and 1989 and involving a 
total of 1,336 patients the frequency of the risk of HIT 
was approximately 3.4%. Remarkably HIT associated 
thrombosis was found only in 1% of patients. In most 
of the studies cited in that review a confirmatory test 
for the diagnosis of HIT was not performed (7).
 Schmitt and Adelman (8) reviewed 23 
randomised or cohort prospective studies of 2160 
patients. Utilising reproducible thrombocytopaenia 
(platelet count less than 100 x 109/l) as criteria in the 
absence of laboratory confirmation, the incidence 
of HIT was found to be 1.1% with intravenous 
porcine heparin and 2.9% with bovine heparin. No 
thrombocytopaenia was observed with subcutaneous 
administration of heparin. This difference however 
was not statistically significant.
 Two well designed randomised studies have 
been described in literature. The first is a study by 
Warkentin et al (9) involving 665 orthopaedic patients 
and comparing the incidence of HIT with standard 
UFH and LMWH. Using a threshold platelet count 
of 150 x109/l, HIT developed in 2.7% of patients 
with standard UFH. None of the patients on LMWH 
developed HIT. The frequency of heparin induced 
antibodies was 7.8% with UFH and 2.2% with 
LMWH.
 The other study was the multicenter trial by 
Lindhoff et al (10) involving 1137 patients randomly 
assigned to therapy with standard UFH or LMWH 
for the treatment of DVT. This study found a 
significantly higher incidence of heparin induced 
antibody formation in the UFH group than in the 
LMWH heparin group (20.7% vs 7.5% p<0.001). 
The patients on short term (5-7 days) treatment with 
LMWH did not develop heparin induced antibodies 
or HIT. Although the frequency of HIT was similar for 
both UFH and long term treatment LMWH groups 
(0.53%) the incidence of thrombosis events was higher 
in the former (50% vs 0%). An important observation 
in this study was the increase in the titre of heparin 
induced antibodies 14 days after stopping heparin 
treatment.
 Analysis of the studies published between 
1996 and 2005 indicate a high incidence of antibody 
formation in patients undergoing cardiac surgery 
(range 25-64%) (11,12).  Despite this high frequency 
the incidence of thrombocytopaenia and thrombosis 
are much lower than in patients receiving prophylactic 
heparin therapy for orthopaedic surgery in which 
the frequency of antibody formation is much lower 
(7.8-14.1%) (13).
 Neurological patients receiving UFH also 
demonstrated a high incidence of antibody 
formation (20.5%) and thrombocytopaenia (2.5%) 
with 80% of HIT patients developing thrombosis 
(14).   However similar patients treated with with 
LMWH demonstrated a much lower incidence 
of antibody formation (1.8%) with no sequlae of 
thrombocytopaenia and thrombosis (15).
 The incidence  of antibody formation in medical 
patients in one large study was found to be 1% with 
an even lower frequency of thrombocytopaenia 
(0.5%). This low incidence of HIT was also seen 
in other studies involving medical in patients but 
the proportion of patients with HIT developing 
thrombosis was high (50-67%) (16-18). Analysis 
of renal patients on haemodialysis also indicate a 
low incidence of antibody formation (combined 
incidence 2.6%) with very few patients noted to 
be thrombocytopenic and none with thrombotic 
complications (19-23).
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 Preliminary results from the CATCH registry 
(Complications After Thrombocytopaenia Caused 
by Heparin) indicate an incidence of HIT in 0.2% of 
patients who have received heparin for more than 
96 hours (n=1020) and 2.1% for patients receiving 
heparin in coronary care units (n=164). Final results 
from this study which aims to clarify the incidence 
evaluation and outcome of HIT in over 7000 patients, 
are keenly awaited (24).
Clinical manifestation of HIT: The predominant clinical 
features of HIT are thrombocytopaenia and the sequlae 
of thrombosis. Despite the thrombocytopaenia, 
which can be severe, bleeding is not a feature of this 
syndrome. Thrombosis though not very common, 
can be extensive resulting in increased morbidity 
and mortality (25).
 Thrombocytopaenia occurs in 90% of patients 
with immune HIT. Typically the thrombocytopaenia 
is of moderate severity with median platelet count 
of approximately 50-70 × 109/l and very few 
patients have platelet counts of less than 15x109/l. 
Ironically these patients are at an even greater risk 
of thrombosis compared to patients with less severe 
thrombocytopaenia (7).
 Thrombocytopaenia by standard definition is 
based on a fall in platelet count below 150x109/l but 
this definition has been found to be inappropriate 
for HIT because of the existence of clinical situations 
where the platelet count may not fall below the  lower 
limit of the reference (26). In about 10% of patients 
with HIT the platelet nadir count never falls to less 
than 150x109/l. This may be because HIT complicates 
a postoperative course that is characterised by 
thrombocytosis and occasionally because of chronic 
thrombocytosis.
 Following a secondary analysis of a clinical trial 
Warkentin et al (27) proposed an improved definition 
for thrombocytopaenia; a fall in platelet count of 50% 
or greater from the postoperative peak. This improved 
definition had superior operating characteristics 
and identified many more patients with HIT while 
retaining the same high specificity as observed with 
the standard definition.
 Thrombosis is the most important complication 
of HIT. Indeed some cases of HIT are only identified 
after development of a new thrombotic event. Both 
arterial and venous thrombo-embolic complications 
are seen in HIT patients (25).
 The thrombosis described in the early studies 
of Weisman et al (3) as well as by Roberts et al (4) 
were mainly arterial in site.  These thrombi appeared 
pale or pearly white in colour and when examined 
microscopically showed platelet rich contents. As 
a result of these observations the term “white clot” 
syndrome was designated for this condition (3).
More recent studies have demonstrated a higher 
incidence of venous thrombosis occurring as part of 
the spectrum of the thrombo-embolic complication 
in HIT patients (26).
 Thrombosis is strongly associated with HIT. In a 
randomised double blind clinical trial involving 665 
patients, eight out of nine patients with HIT developed 
thrombosis compared with 117 of 656 patients without 
HIT (88.9% vs 17.8% odds ratio 36.9% p< 0.001). In 
this study venous thrombosis predominated with 
seven patients developing DVT and pulmonary 
embolism, while one patient developed mesenteric 
artery thrombosis (13).
 In a 14 year retrospective study carried out by 
Warkentin and Kelton (26) on 127 patients with HIT, 61% 
of patients had venous thrombotic events while arterial 
events occurred in 14% patients giving a ratio of 4:1. 
The venous thrombotic events included DVT and PE. 
Limb ischaemia, myocardial infarction and thrombotic 
stroke formed the spectrum of arterial events. Two cases 
of adrenal haemorrhage and one case of sudden death 
were also reported in this study (26).
 Nand et al (28) found an overall incidence of 29% 
for thromboembolic complication in their study of 108 
consecutive patients with HIT. Venous thrombosis 
was more frequent than arterial thrombosis (62% vs 
25%; ratioV/A   2.5:1). Pulmonary embolism was seen 
in two patients and 14 patients had DVT. The arterial 
events seen in this study included limb ischaemia, 
cerebrovascular accidens and myocardial infarction 
secondary to by pass graft occlusion. A mortality rate 
of 15.6% was found in this study.
 Skin manifestations of HIT have been reported 
in literature. Warkentin (29) reported six patients with 
skin lesions and serological evidence of HIT. Four 
patients developed painful erythromatous plaques 
while the other two manifested overt skin necrosis. 
Two of the patients developed thrombocytopaenia 
and both had severe venous and arterial thrombosis. 
All six patients had received UFH for postoperative 
prophylaxis with skin manifestations localised to the 
injection site. Tietge et al (30) presented a case report 
of a 76 year old male with skin necrosis induced by 
subcutaneous injection of LMWH . This adverse event 
occurred at a distant position from heparin injection 
sites with thrombocytopaenia being notably absent. 
CLINICAL DIAGNOSIS OF HIT 
Thrombocytopaenia in hospitalised patients can result 
from numerous causes. These include bone marrow 
failure, haemodilution, bacteraemia, disseminated 
vascular coagulation and non heparin medication. 
Although HIT may not be the most common cause of 
acute thrombocytopaenia, failure to recognise it may 
cause significant morbidity and mortality.
 Once thrombocytopaenia is confirmed, the 
diagnosis of HIT should be formulated on the basis 
of clinical criteria and the in vitro demonstration of 
heparin dependant antibodies (31).
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 To evaluate the clinical probability of HIT various 
scoring systems have been proposed. A clinical scoring 
system, the four T’s based upon the assessment of 
Thrombocytopaenia, Timing, Thrombosis and absence 
of other causes for thrombocytopaenia have been 
proposed by Warkentin (32). Preliminary evaluation 
suggests that HIT is unlikely when a low score (<3) 
is obtained and very likely with a high score (>6). 
An intermediate score (4-5) indicates a clinical profile 
compatible with HIT but other causes such as sepsis 
may be present. Laboratory testing for HIT antibodies 
is especially valuable in these patients (32).
 Frequent platelet count monitoring beginning 
on day 5 of heparin use is important for the early 
diagnosis of HIT and should be performed in high 
risk patients especially cardiac and orthopaedic 
surgery patients using UFH. Patients receiving 
therapeutic doses of UFH should have their platelet 
count monitored on alternate days until day 14 or 
until UFH is stopped whichever occurs first. For 
patients who have received heparin in the past 100 
days prior to re- exposure, a baseline platelet count 
should be obtained before commencing heparin and 
a repeat within 24 hours followed by alternate day 
monitoring (33).
Pathogenesis of HIT: The major determinant in the 
pathogenesis of immune HIT is the formation 
of heparin/platelet factor complexes and the 
development of antibodies directed against these 
complexes (34).
Table 1
Testimating pretest probability of HIT: the “four T’s” 
                Points (0,1 or 2 for each of four categories: maximum possible score = 8 
         1         1           0 
Thrombocytospaenia  >50% platelet fall to  30-50% platelet fall or <30% platelet fall or
  Nadir> 20×109/l  nadir 10-19×109/1  nadir <10×109/1 
Timing of onset of  day 5-10, or  > day 10 or timing unclear  < day 4 (no recent 
platelet fall (or other  < day 1 with recent   heparin) 
sequalae of HIT)  heparin (past 30 days)   
day 0= first day of    
heparin therapy    
Thrombosis or other  Proven new thrombosis:  Progressive or recurrent  None
sequalae  skin necrosis or acute  thrombosis, erythromatous   
 systemic reaction after  skin lesions, suspected  
 l.v heparin bolus  thrombosis (not proven)  
•Ther cause(s) of  None evident  Possible  Definite 
platelet fall    
Pretest probability score: 6-8 high  4-5 intermediate  0-3 low 
 The binding of heparin induces a conformational 
change exposing several antigenic epitopes of the PF4 
molecule between the 3rd and 4th cysteine residues 
(35). This region appears to be the major antigenic 
site with a second site (site 2) identified  at proline 34 
which is the amino acid preceding the third cysteine 
moiety
 The heparin-platelet factor 4 complexes with the 
exposed antigenic sites are  recognised by antigen 
presenting cells and subsequently these complexes are 
presented to helper T cells resulting in the production 
of antibodies. A number of studies have confirmed the 
highly immunogenic nature of  HPF4 complexes and 
the role of T cells in anti HPF4 antibody formation 
(36, 37).
 The complexes of heparin PF4 form on the surface 
of activated platelets where they are subsequently 
recognised by HIT antibodies. HIT antibodies 
bind to HPF4 complexes on platelets through their 
Fab portion. The HPF4 antibody also binds to Fc 
receptors on platelets thereby inducing further platelet 
activation and enhancing more expression of PF4 
moieties on the platelet surface (38, 39).
 HIT is also associated with direct endothelial 
damage. Heparan sulphate is a glycosaminoglycan 
found on endothelial cells and is less sulphated than 
heparin. Excess platelet factor 4 secondary to  platelet 
activation can bind to heparin and these heparin- PF4 
complexes are recognised by HIT antibodies resulting 
in immune mediated vascular injury with endothelial 
activation (40).
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Figure 1
with very high concentrations of heparin. This test 
is regarded as the “gold standard” for laboratory 
diagnosis. 
 The heparin induced platelet activation assay 
(HIPA), developed by Greinacher and colleagues 
in 1991 is a platelet aggregation assay performed in 
microtitre  wells using washed platelets. In this test 
visual detection is employed for determination of 
platelet aggregation (43).
 Following molecular characterisation and 
antigenicity of the heparin/PF4 complexes, 
immunoassays have been developed for the detection 
of heparin induced antibodies. The first enzyme linked 
immunoabsorbent assay (ELISA) was developed 
in 1995 by Amiral et al (44) using macromolecular 
complexes of HPF4 as the target antigen immobilised 
to a solid phase.  Commercial assays using PF4/ 
polyvinyl sulphonate as target antigens have been 
subsequently developed.
LABORATORY TESTING FOR HIT
Laboratory testing for the diagnosis of HIT have 
evolved following better understanding of its immuno 
pathological mechanisms. Two types of laboratory 
tests are available for establishing a diagnosis of HIT 
functional assays and immunoassays.
 Functional assays are tests that are based on 
platelet aggregation or activation. Frantantoni et al 
in 1975 (41) described the first platelet aggregation 
test following the observation that heparin added to 
platelet rich plasma of HIT patients caused aggregation. 
Further the serum from HIT patients also effected the 
release of 3H – serotonin from normal platelets.
 In 1986 Sheridan et al (42) developed a more 
sensitive and specific assay that measured platelet 
release instead of aggregation. The principle of this 
test is based on the release of C-serotonin by washed 
platelets at therapeutic concentrations and inhibition 
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Table 2
Sensitivity and specificity of selected assays in HIT
Diagnostic Sensitivity Specificity  Specificity
assay  (%) (%)  (%)
  (Early platelet  (Late platelet
  fall < 4d)  fall > d5)
SRA 90-98 >95 80-97
HIPA 90-98 >95 80-97
PAT 35-85 90 82
HPF4 ELISA 90% >95 50-93
Combination (sensitive functional and 
antigen  100 >95 80-97 
  MANAGEMENT OF HIT AND HIT/T
Heparin induced thrombocytopaenia poses a serious 
challenge for patients who require anticoagulation. 
Available evidence indicates that the risk for 
thrombosis in the days to weeks after stopping 
heparin therapy is at least 20% and possibly as high 
as 50% in HIT patients presenting with isolated 
thrombocytopaenia. This evidence supports the 
view that alternate therapy with a rapidly acting 
anticoagulant should be initiated when heparin 
therapy is discontinued (45).
 The most essential element in the treatment 
of HIT and HIT/T remains discontinuation of all 
heparin including heparin line flushes, subcutaneous 
heparin and heparin coated indwelling catheters. 
The persistent prothrombotic tendency associated 
with HIT, the presence of thrombus in HIT/T and 
the patients original indication for heparin therapy 
all warrant the use of an alternative anticoagulant 
agent after heparin cessation (46).
 The optimal anticoagulant therapy for HIT 
remains uncertain. Oral anticoagulants such as 
warfarin are ineffective and potentially deleterious 
during the first several days of use in patients with 
acute HIT. A syndrome of venous limb gangrene 
has been linked with procoagulant/anticoagulant 
balance during the use of warfarin to treat HIT (47). 
Warkentin and colleagues (48) recommend that oral 
anticoagulants should not be given for at least 3-5 
discontinuation of heparin and preferably not before 
platelet count recovery.
 The use of alternative anticoagulants is advocated 
for the treatment of patients with HIT based on the 
understanding that these agents do not cross react 
with anti HPF4 antibodies and are effective and safe 
for the prophylaxis or treatment of thrombosis (46).
 LMWH appear to be attractive for the treatment of 
HIT/T patients in view of their reduced immunogenic 
potential as compared to UFH. However LMWH 
have a high in vitro cross reactivity rate with heparin 
dependant antibodies reaching almost 100% in 
some very sensitive assays. LMWH less likely, but 
can also cause HIT, and when used in its treatment 
there is a significant risk of recurrent or progressive 
thrombocytopaenia with or without thrombosis. As 
a result of these drawbacks and with the availability 
of other anticoagulants options LMWH are not 
recommended for the management of patients with 
HIT (48).
 Newer anticoagulants which have been used 
with varying degrees of success for the management 
of HIT/T include danaparoid sodium (Ogaran), 
lepirudin (Refludan TM) and argatroban. Danaparoid 
is a mixture of low molecular weight anticoagulant 
glycosaminoglycans. In contrast to LMWH it 
contains no heparin fragments and has a different 
glycosaminoglycans back bone structure.
 Earlier studies with danaparoid carried out 
by Chong et al (49) demonstrated an in vitro cross 
reactivity rate with HIT antibodies of 18%. Other 
reports indicate in vitro cross reactivity rates of 10-
50% depending on the sensitivity of the method used 
but in vivo cross reactivity has not been commonly 
observed (50).  Danaparoid treatment without prior 
in vitro cross reactivity is therefore assumed to be a 
reasonable therapeutic option (51).
 Magnani (52) presented an overview of 230 
patients treated with ogaran on a “compassionate” 
basis. 92.8% of patients responded adequately to 
treatment as gauged by recovery or stabilisation of 
platelet counts and control of thrombotic events. 
A total of 59 deaths were reported of which seven 
(30%) were attributed to orgaran use. The remaining 
52 deaths were due to severity of the preexisting 
disorders (52).
 Treatment failures with Danaparoid have 
been reported. In the overview by Magnani 
(51), there were 15 treatment failures in patients 
receiving danaparoid and also within 48 hours 
of stopping orgaran therapy. Treatment failure 
manifested as bleeding (two patients), persistence 
of thrombocytopaenia (five patients), appearance 
of thrombocytopaenia (four patients) and thrombo 
embolic events (four patients) (52).
 Danaparoid is a useful and safe alternative to 
other anticoagulants in HIT patients and can be used 
in a variety of clinical settings with success and may 
be considered as first choice alternative parentral 
anticoagulant in patients due to its relative low cost 
and ease of use.
 Hirudins are a group of highly homologous 
polypeptides extracted from the salivary glands of 
the medicinal leech Hirudo medicinalis.     They have an 
extremely high and specific binding for thrombin and 
are consequently potent anticoagulants. Hirudins have 
the property of inhibiting platelet activation induced by 
thrombin and efficiently inhibit fibrin bound thrombin. 
Recombinant hirudins have now been produced and 
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have been shown to be effective against venous thrombi 
and platelet rich thrombi in arteries.
 Lepirudin is a recombinant form of hirudin 
derived from yeast cells and is a highly specific direct 
and irreversible inhibitor of thrombin binding to it 
with a ratio of 1:1. It differs structurally from heparin 
thus eliminating cross reactivity and can be monitored 
using the ubiquitous activated partial thromboplastin 
time assay (aPTT) (50).
 A meta-analysis of two prospective studies in 
patients with HIT and TEC showed a reduction in the 
combined endpoint of death, limb amputation and 
new TECs in lepuridin treated patients compared with 
a  historical  control population (a placebo control trial 
was considered unethical given the natural history 
of HIT/T). These better outcomes resulted primarily 
from a statistically significant reduction of new TECs 
(10.1% vs 27.2%) at day 35 (53).
 Agatroban is a direct competitive inhibitor of 
thrombin derived from L-arginine. It binds reversibly 
to the thrombin catalytic site and inhibits the reactions 
that are induced by soluble and clot bound thrombin. 
In addition agatroban inhibits activation of factors V, 
VIII XIII and protein.  Agatroban is monitored by the 
aPTT aiming for a target  of 1.5-3 times the control 
value (53).  Antibody formation has not been reported 
with agatroban (54).
 Two large multicentre prospective studies with 
historical controls evaluating the efficacy and safety 
of agatroban in HIT and HIT/T have been reported. 
In the first study (ARG 911) the composite end point 
incidence (death, amputation or new thrombosis) 
was significantly reduced in the agatroban HIT 
treated patients versus control.  For the HIT/T 
patients the time to event analysis clearly favored the 
agatroban treated arm with significant reduction in 
new thrombotic events and death due to thrombosis. 
An interesting observation was the more rapid 
rise in platelet count in agatroban treated patients. 
Major bleeding rates were not different between the 
agatroban treated patients and control subjects in 
either study arms (55).
 The second multicentre non randomized 
prospective study showed similar results regarding 
time to event analysis of composite endpoint with a 
significant reduction in the incidence of death due 
to thrombosis in patients with HIT/T (55).
 Fondaparinux is a new synthetic selective 
inhibitor of activated coagulation factor X and has been 
shown to be an effective and safe antithrombotic agent 
in a number of thrombotic disorders . Fondaparinux 
does not bind to PF4 and has negligible cross reactivity 
with HIT antibodies. Savi et al (56) performed a 
serologic study to determine cross reactivity of HIT 
sera with fondaparinux in a prospective blinded 
study. This study showed that fondaparinux was 
significantly less reactive than UFH in the evaluable 
assays. The results of this study favor the possibility 
of fondaparinux as therapeutic option for prophylaxis 
and treatment of thrombosis in HIT patients (56).
 Adjunctive treatments in HIT have not been 
assessed systematically. They may be considered 
as additional treatment options in individual 
patients and include antiplatelet agents such as 
aspirin, iloprost and platelet glycoprotein 11b/111a 
inhibitors (57).    Intravenous immunoglobulins, (IVg), 
have been shown to block activation of platelets by 
HIT antibodies and there have been case reports of 
increased platelet counts after administration of 
IVIg (58). Plasmapheresis as a therapeutic adjuvant 
has been cited in a number of case studies where 
a dramatic improvement in the plate count and 
marked reduction of thrombosis have been reported 
(59-61).
 HIT is now a well recognised adverse effect of 
heparin therapy. Though uncommon, recognition 
of HIT is important because of the potential to 
develop serious complications of thrombosis. The 
formation of heparin-platelet factor4 complexes and 
the subsequent but variable evolution of the humoral 
response are central to the pathogenesis, clinical 
manifestation, laboratory diagnosis and treatment 
of HIT.
 The frequency of heparin induced antibody 
formation, thrombocytopaenia and thrombotic 
complications vary in different populations, with 
orthopaedic and medical in-patients demonstrating a 
higher incidence of thrombo- embolic complications 
following HIT. The diagnosis of HIT requires 
awareness and a high index of suspicion coupled with 
the results of highly sensitive and specific laboratory 
tests. Treatment consists of immediate cessation of 
heparin therapy and institution of anticoagulants 
that do not exhibit cross reactivity to HIT antibodies. 
Despite the increased awareness there is a significant 
degree of morbidity and mortality which can be 
prevented by early recognition and platelet count 
monitoring.
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